Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
543.70M
Enterprise Value
-
Income
-
Sales
-
Book/sh
-
Cash/sh
-
Employees
-
IPO
May 01, 1992
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
-
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
-
Insider Trans
-
Inst Own
38.27%
Inst Trans
-
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
0.36%
SMA50
-8.45%
SMA200
-1.78%
Trades
Shs Outstand
30.41M
Shs Float
30.40M
52W High
22.67 -21.13%
52W Low
15.66 14.18%
Volatility
2.97% 3.28%
ATR (14)
0.54
RSI (14)
45.21
Beta
0.74
Rel Volume
0.80
Avg Volume
144.85K
Volume
109,850
Perf Week
3.71%
Perf Month
-8.59%
Perf Quarter
-7.12%
Perf Half Y
2.70%
Perf YTD
6.56%
Perf Year
9.36%
Perf 3Y
51.78%
Perf 5Y
-12.56%
Perf 10Y
5.90%
Recom
-
Target Price
-
Prev Close
17.92
Price
17.88
Change %
-0.22%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahai Chris LaVictoireDirectorJul 16 '26Buy19.9252710,498527Jul 20 02:36 PM
Pittard ChristianDirectorDec 16 '25Buy16.887,923133,7557,923Dec 18 11:16 AM
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Ph.D.Dr. Daniel R. Omstead M.S
Chief Investment OfficerMr. Peter Branner